PEPCID
LOE ApproachingNDAORALTABLET
Approved
Oct 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PEPCID (famotidine) is an oral histamine H2-receptor antagonist approved in 1986 for the treatment of acid-reflux disorders including peptic ulcer disease and gastroesophageal reflux disease (GERD). It reduces gastric acid secretion by blocking histamine-mediated acid production in the stomach. This is a mature, well-established therapeutic agent in the gastrointestinal category.
$0.836MPart D
LOE ApproachingDeclining
Low Medicare spending and claim volume signal a mature, declining product with minimal commercial team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings signal minimal career opportunity; roles on PEPCID are maintenance-focused and unlikely to provide advancement into growth-stage or innovative product teams. This assignment is typically a transition role or portfolio manager responsibility rather than a career-building opportunity.
Brand ManagerField Sales Representative
Worked on PEPCID at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.